Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cusatuzumab - argenx

Next Previous
X
Search
Drug Profile

Cusatuzumab - argenx

Alternative Names: Anti-CD70 SIMPLE Antibody; ARGX-110; JNJ 74494550; JNJ-4550

Latest Information Update: 28 Nov 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator arGEN-X
  • Developer argenx; Cilag GmbH International; OncoVerity
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD70 antigen inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Cutaneous T-cell lymphoma; Myelodysplastic syndromes
  • Phase I/II Haematological malignancies; Solid tumours
  • No development reported Autoimmune disorders; Nasopharyngeal cancer

Most Recent Events

  • 22 Jul 2024 Phase-II clinical trials in Acute myeloid leukaemia (Combination therapy, First-line therapy) in Switzerland, Canada and Germany (IV) (NCT06384261)
  • 22 Jul 2024 Phase-II clinical trials in Acute myeloid leukaemia (First-line therapy, Combination therapy) in USA (IV) (NCT06384261)
  • 25 Apr 2024 OncoVerity plans a phase II trial in Acute myeloid leukemia (Combination therapy, First-line therapy) (IV) in May 2024 (NCT06384261)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top